About nanovibronix inc - NAOV
NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Tyler, TX.
NAOV At a Glance
NanoVibronix, Inc.
969 Pruitt Avenue
Tyler, Texas 77569
| Phone | 1-914-233-3004 | Revenue | 2.56M | |
| Industry | Medical Specialties | Net Income | -3,705,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 12.046% | |
| Fiscal Year-end | 12 / 2025 | Employees | 31 | |
| View SEC Filings |
NAOV Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.685 |
| Price to Book Ratio | 3.922 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.311 |
| Enterprise Value to Sales | 0.436 |
| Total Debt to Enterprise Value | 0.104 |
NAOV Efficiency
| Revenue/Employee | 82,516.129 |
| Income Per Employee | -119,516.129 |
| Receivables Turnover | 9.545 |
| Total Asset Turnover | 0.497 |
NAOV Liquidity
| Current Ratio | 1.224 |
| Quick Ratio | 0.419 |
| Cash Ratio | 0.276 |
NAOV Profitability
| Gross Margin | 58.952 |
| Operating Margin | -140.031 |
| Pretax Margin | -144.097 |
| Net Margin | -144.84 |
| Return on Assets | -71.921 |
| Return on Equity | -160.563 |
| Return on Total Capital | -498.654 |
| Return on Invested Capital | -158.367 |
NAOV Capital Structure
| Total Debt to Total Equity | 18.501 |
| Total Debt to Total Capital | 15.612 |
| Total Debt to Total Assets | 3.196 |
| Long-Term Debt to Equity | 10.207 |
| Long-Term Debt to Total Capital | 8.614 |